U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07236099) titled 'Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis' on Oct. 27.
Brief Summary: Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Prurigo Nodularis (PN)
Intervention:
DRUG: ICP-322
ICP-322 Tablets
DRUG: Placebo
ICP-332 Placebo Tablets
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....